Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Feb 14, 2005; 11(6): 778-784
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.778
Published online Feb 14, 2005. doi: 10.3748/wjg.v11.i6.778
Table 1 Frequency of LOH and MSI of tumor suppressor genes in sporadic colorectal cancers.
Marker | Informative /Total (%) | LOH/Informative (%) | MSI No./Total (%) |
NM23-H1 | 125/207 (60.4) | 43/125 (31.6) | 4/164 (2.4) |
APC | 121/207 (58.5) | 56/121 (47.8) | 10/151 (6.6)1 |
Tp53.alu | 103/207 (49.8) | 67/103 (65.0) | 1/140 (0.7) |
HPC1 | 127/207 (61.4) | 15/127 (11.8) | 6/192 (3.1) |
D8S254 | 89/207 (43.0) | 46/89 (51.7) | 5/161 (3.1) |
DCC | 98/207 (47.3) | 63/98 (64.3) | 3/144 (2.1) |
hMSH2 | 153/207 (73.9) | 24/153 (15.7) | 19/183 (10.4)1 |
hMLH1 | 99/207 (47.8) | 26/99 (26.3) | 11/181 (6.1) |
MET | 91/207 (44.0) | 27/91 (29.7) | 7/180 (3.9) |
Tp53.pcr15 | 80/207 (38.6) | 31/80 (38.8) | 5/174 (2.9) |
MYCL1 | 110/207 (53.1) | 38/110 (34.5) | 5/169 (3.0) |
Bat-25 | 30/207 (14.5) | 3/30 (10) | 22/204 (9.8)1 |
Bat-26 | 41/207 (19.8) | 4/41 (4.4) | 15/203 (7.4)1 |
Mfd15 | 33/207 (15.9) | 2/33 (7.2) | 9/205 (4.4)1 |
Table 2 Comparison between clinico-pathological features of loss of heterozygosity-high and loss of heterozygosity-low in colorectal cancer, n (%).
Features | Total | LOH-high | LOH-low | P |
Number of cases | 207 | 93 (44.9) | 114 (55.1) | |
Age (yr) | 66.2±12.4 | 67.2±12.4 | 65.4±12.3 | 0.2921 |
Gender (male/female) | 139/68 | 61/32 | 78/36 | 0.7782 |
Location of tumor | ||||
Right colon | 37 (17.9) | 16 (17.2) | 21 (18.4) | 0.5443 |
Left colon | 85 (41.1) | 42 (45.2) | 43 (37.7) | |
Rectum | 85 (41.1) | 35 (37.6) | 50 (43.9) | |
TNM stage | ||||
I | 25 (12.1) | 7 (7.5) | 18 (15.8) | <0.0014 |
II | 73 (35.3) | 22 (23.7) | 51 (44.7) | |
III | 68 (32.9) | 37 (39.8) | 31 (27.2) | |
IV | 41 (19.8) | 27 (29.0) | 14 (12.3) | |
Invasive pattern | ||||
Expanding | 52 (25.1) | 20 (21.5) | 32 (28.1) | 0.2862 |
Infiltrative | 155 (74.9) | 73 (78.5) | 82 (71.9) | |
Grade | ||||
Well-differentiated | 5 (2.4) | 2 (2.2) | 3 (2.6) | 0.2633 |
Moderate differentiated | 182 (87.9) | 81 (87.0) | 101 (88.6) | |
Poorly differentiated | 20 (9.7) | 10 (10.8) | 10 (8.8) | |
Lymphovascular invasion | ||||
Yes | 48 (23.2) | 27 (56.3) | 21 (43.7) | 0.1022 |
No | 159 (76.8) | 66 (41.5) | 93 (58.5) | |
Mucin production | ||||
Yes | 29 (14.0) | 9 (9.7) | 20 (17.5) | 0.1552 |
No | 178 (86.0) | 84 (90.3) | 94 (82.5) |
Table 3 Comparison between clinico-pathological features of MSI-H and MSS in colorectal cancer, n (%).
Features | Total | MSI-H | MSS | P |
Number of cases (%) | 207 | 15 (7.25) | 192 (92.7) | |
Age (yr) | 66.2±12.4 | 69.7±14.8 | 65.9±12.2 | 0.2481 |
Gender(male/female) | 139/68 | 8/7 | 131/61 | 0.3692 |
Location of tumor | ||||
Right colon | 37 (17.9) | 7 (46.7) | 30 (15.6) | 0.0053 |
Left colon | 85 (41.1) | 2 (13.3) | 83 (43.2) | |
Rectum | 85 (41.1) | 6 (40.0) | 79 (41.2) | |
TNM stage | ||||
I | 25 (14.2) | 1 (6.7) | 24 (12.5) | 0.7804 |
II | 73 (36.8) | 6 (40.0) | 67 (34.9) | |
III | 68 (31.6) | 6 (40.0) | 62 (32.3) | |
IV | 41 (17.4) | 2 (13.3) | 39 (20.3) | |
Invasive pattern | ||||
Expanding | 52 (25.1) | 4 (26.7) | 48 (25.0) | 1.02 |
Infiltrative | 155 (74.9) | 11 (73.3) | 144 (75.0) | |
Grade of differentiation | ||||
Well | 5 (2.4) | 0 | 5 (2.6) | <0.0013 |
Moderate | 182 (87.9) | 9 (60.0) | 173 (90.1) | |
Poor | 20 (9.7) | 6 (40.0) | 14 (7.3) | |
Lymphovascular invasion | ||||
Yes | 48 (23.2) | 1 (6.7) | 47 (24.5) | 0.2092 |
No | 159 (76.8) | 14 (93.3) | 145 (75.5) | |
Mucin component | ||||
Yes | 29 (14.0) | 7 (46.7) | 22 (11.5) | 0.0012 |
No | 178 (86.0) | 8 (53.3) | 170 (88.5) |
Table 4 Correlation of the clinico-pathological factors with three-year disease-free survival in potentially cured colorectal cancer patients (stage I, II, III patients).
Variables | Number of cases | 3-yr disease -free survival | P1 |
Gender | |||
Male | 116 | 70 | 0.614 |
Female | 50 | 75 | |
Preoperative CEA level | |||
<5 ng/mL | 80 | 82 | 0.003 |
>5 ng/mL | 86 | 63 | |
TNM stage | |||
I | 25 | 95 | <0.001 |
II | 73 | 84 | |
III | 68 | 47 | |
Lymphovascular permeation | |||
No | 129 | 73 | 0.091 |
Yes | 37 | 63 | |
Invasive pattern of tumor | |||
Expansive | 45 | 73 | 0.517 |
Infiltrative | 121 | 68 | |
Grade of differentiation | |||
Well | 3 | 100 | 0.004 |
Moderate | 146 | 75 | |
Poor | 17 | 48 | |
Mucinous component | |||
<50% | 143 | 72 | 0.642 |
>50% | 23 | 68 | |
Microsatellite instability | |||
MSI-H | 13 | 69 | 0.91 |
MSS | 153 | 71 | |
LOH status | |||
Low | 100 | 84 | <0.001 |
High | 66 | 50 |
Table 5 Multivariate analysis1.
Factors | Hazard ratio | 95% CI | P |
LOH (High vs Low) | 3.18 | 1.68-5.98 | <0.001 |
TNM | 3.31 | 1.82-6.01 | <0.001 |
CEA level | |||
>5 ng/mL vs <5 ng/mL | 2.3 | 1.21-4.37 | 0.011 |
Grade of differentiation | 1.12 | 0.45-2.77 | 0.791 |
Lymphovascular invasion | 1 | 0.49-2.01 | 0.981 |
Table 6 Informative markers that influenced three-year DFS in potentially cured colorectal cancer patients (stage I, II, III patients).
Markers | Number of cases | 3-yr disease-free survival | P1 |
Nm23-H1 | |||
Non-LOH | 68 | 75 | 0.266 |
LOH | 28 | 62 | |
APC | |||
Non-LOH | 54 | 75 | 0.881 |
LOH | 45 | 72 | |
Tp53.alu | |||
Non-LOH | 29 | 92 | <0.001 |
LOH | 55 | 51 | |
HPC1 | |||
Non-LOH | 87 | 75 | 0.743 |
LOH | 12 | 70 | |
D8S254 | |||
Non-LOH | 39 | 75 | 0.03 |
LOH | 31 | 52 | |
DCC | |||
Non-LOH | 27 | 79 | 0.042 |
LOH | 45 | 55 | |
MSH2 | |||
Non-LOH | 107 | 73 | 0.972 |
LOH | 15 | 75 | |
MLH1 | |||
Non-LOH | 62 | 66 | 0.287 |
LOH | 19 | 57 | |
Met ONC | |||
Non-LOH | 50 | 72 | 0.35 |
LOH | 16 | 64 | |
Tp53.pcr15 | |||
Non-LOH | 42 | 76 | <0.001 |
LOH | 20 | 33 | |
MYCL1 | |||
Non-LOH | 59 | 71 | 0.421 |
LOH | 29 | 65 |
- Citation: Chang SC, Lin JK, Lin TC, Liang WY. Loss of heterozygosity: An independent prognostic factor of colorectal cancer. World J Gastroenterol 2005; 11(6): 778-784
- URL: https://www.wjgnet.com/1007-9327/full/v11/i6/778.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i6.778